Expression data from MDA-MB-231 cell line treated with Zoledronate, or Fluvastatin, or mock-treated control cells.

ABSTRACT: Statins and bisphosponates (BPs) are two distinct classes of isoprenoid pathway inhibitors targeting HMG-CoA reductase (upstream enzyme) and Farnesyl-pyrophospate synthase (downstream enzyme) respectively. Here we conducted a comparative study of two representatives of these classes, fluvastatin (Fluva) and Zoledronate (Zol), to assess the differences in their in vivo metastatic potentials and pharmacogenomic profiles. Both drugs, being administered after emergence of detectable metastases, appeared to be potent metastasis inhibitors in MDA-MB-231 breast cancer metastasis model. We observed a reduced number of metastatic sites under Fluva, but not Zol treatment. Combinatorial in vivo treatment by Fluva and Zol showed no synergy for these drugs, as reported earlier on the basis of in vitro

ORGANISM(S): Homo sapiens

SUBMITTER: Nadejda Vintonenko 

PROVIDER: E-GEOD-33552 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress